Ahead of BIO International Convention, a panel of industry leaders from bioprocess, cell‑line development, CDMOs and advanced‑therapy service providers discussed with 24/7 Biopharma how rising molecular complexity, cost pressures and evolving market dynamics are reshaping development and manufacturing. From next‑generation modalities and data‑driven process design to new partnership and operating models, this roundtable explored practical strategies for accelerating translational decisions, scaling manufacture and de‑risking the path from discovery to commercial supply.
Author: Amit Dua, Global Head of Strategy, Marketing & Product Management – Bioprocess
Q. What are the biggest trends currently shaping your organization and the wider life sciences sector?
AD. Much of what shapes our thinking comes directly from conversations with customers. When you spend time in development labs and manufacturing facilities across different regions, consistent themes emerge.
The pipeline is becoming significantly more complex. The rise of multispecifics, antibody-drug conjugates, and other emerging modalities is placing unprecedented demands on downstream purification. These molecules are inherently harder to capture and polish with precision. We hear this consistently from development teams who are finding that processes designed for conventional mAbs simply do not translate.
Alongside this, manufacturers are under real pressure to improve process efficiency and reduce cost of goods without compromising quality. As companies build out global manufacturing networks, the need for processes that are robust and transferable across sites and regions has become a recurring theme.
For us, those signals from customers are what orient our innovation, not the other way around.
Q. How are changing market conditions influencing your strategy and priorities for the coming year?
AD. The market dynamic we hear most often is growth alongside increasing pressure. Pipelines are expanding, but cost constraints remain, and at the same time many established therapies are coming off patent. That is putting real focus on how quickly new drugs can move through development and into the market to replace that revenue.
That is directly shaping our innovation strategy. We are focused on helping customers move faster and operate more efficiently, which means prioritizing innovation where it has the greatest impact. For established mAbs, that is next generation purification approaches that can deliver clear gains in performance and productivity. For newer mAb variants, it is about developing new solutions that can handle increasing molecule diversity more effectively and improve yield.
We are also investing in how we support customers globally. As companies expand across geographies, consistency, risk and speed of execution all become critical. Through our Bioprocessing Applications Labs network, we are set up to provide local, hands-on support while maintaining a consistent global approach, helping customers scale, transfer and operate with greater confidence.
Q. What innovations or developments are you most excited about within your area of expertise?
AD. Resin design has advanced considerably, and what is most interesting is not any single development, but the overall direction of innovation. We are seeing continued progress in core technologies like bead and ligand design, which are helping to improve performance, consistency and overall process economics in meaningful ways.
What is equally compelling is the shift in how customers are applying these technologies. There is a move away from optimizing individual chromatography steps in isolation toward designing entire purification workflows for overall efficiency. This more mature approach consistently produces better outcomes.
Data is also playing a much bigger role. We are seeing teams use data more effectively, and increasingly turning to digital solutions to accelerate development, optimize processes and make better decisions earlier. That is helping shift the model from reactive problem solving to more predictive and efficient development.
For us, what is particularly exciting is where these areas come together. Our strength in bead development, combined with how we apply data and work alongside customers, allows us to create solutions that are not just technically strong, but that deliver real impact in a commercial environment.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is your organization helping to address them?
AD. The challenge we hear most consistently is managing increasing molecular complexity against aggressive timelines. At the same time, the broader landscape is shifting quickly. Many established drugs are coming off patent, and new therapies are not moving through development fast enough to replace that revenue. We are also seeing innovation accelerate in markets like China, where development can be faster and more cost-effective, putting additional pressure on global players.
This is forcing companies to rethink how they operate, what capabilities they build internally, where they partner, and how they structure their manufacturing and development infrastructure to stay competitive. Increasingly, success depends on being able to move quickly across both established and emerging modalities.
This is where our bioprocessing business is focused. Through our global technical team and Bioprocessing Applications Lab network, we work alongside customers to help accelerate development and solve challenges across a wide range of modalities. Just as importantly, we support customers across the full lifecycle, from strengthening security of supply and managing risk, to improving cost and performance, supported by our purification technologies and expertise across supply chain, regulatory and quality.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO International this year?
AD. The insights we are acting on have been shaped by what we have been hearing from customers around the world over the past year or two.
Downstream processing is increasingly a competitive differentiator, not just a necessary step. As upstream titers continue to rise, purification has to keep pace, or it becomes the constraint that limits everything else. That shift in mindset is something we believe the industry has been looking to us for to solve and take a leading role in
We also want to reinforce the value of genuine technical partnership. The complexity of modern purification challenges, particularly at scale and across global sites, means that materials alone are not sufficient. The customers making the most progress are those combining strong process science with external expertise and treating that relationship as truly strategic and collaborative.
Ultimately, our focus is on helping customers build downstream processes that are efficient, scalable, and resilient, because that is what they tell us they need to reliably deliver therapies to patients.
Author: John Gill, VP & Scientific Leader- Cell Line Development.
Q. What are the biggest trends currently shaping your organization and the wider life sciences sector?
JG. One of the biggest trends shaping both Abzena and the wider life sciences sector is the rapid growth of next-generation biologics, including bispecifics, fusion proteins and increasingly sophisticated bioconjugates such as antibody-oligonucleotide conjugates. These modalities are creating exciting new therapeutic opportunities, but they also bring greater scientific, technical, and manufacturing complexity.
As a result, success now depends not only on a deep understanding of the science required to design and de-risk these molecules, but also on the ability to scale and manufacture them efficiently with future commercial requirements in mind. At the center of this is the need for robust, adaptable production platforms, including cell line development and other enabling technologies that can accommodate the increasing diversity and complexity of emerging therapeutic formats.
Q. How are changing market conditions influencing your strategy & priorities for the coming year?
JG. Changing market conditions are reinforcing our belief that Abzena is in the right place at the right time. The industry is increasingly focused on advanced biologics and bioconjugates, and our scientific and technical capabilities are well aligned to support companies developing these complex next-generation medicines.
For the coming year, this means continuing to strengthen our ability to improve manufacturing efficiency, reduce development risk and support programs as they progress towards later-stage clinical development, Phase III, and ultimately commercial supply. Our priority is to ensure that promising science can be translated into manufacturable, scalable and commercially viable products.
Q. What innovations or developments are you most excited about within your areas of expertise?
JG. I am particularly excited by innovations that make complex biologic and bioconjugate development more versatile, efficient and scalable. This includes the development of better, more adaptable cell line development platforms that can support a broader range of molecular formats and help accelerate early development decisions.
I am also excited by the move towards more contiguous downstream processes for antibody purification and conjugation. By reducing process breaks, shortening timelines and improving control, these approaches have the potential to reduce time, cost and risk, while improving the path from development into scalable manufacture.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is Abzena helping to address them?
JG. One of the biggest challenges facing biopharma companies today is convincing investors and other stakeholders that next-generation drugs are not only scientifically exciting, but also investable and manufacturable. Companies need to connect compelling early proof-of-concept data with a credible path to making the drug at scale. Abzena helps address this by combining expertise in diverse molecular design with practical experience in drug development and manufacturing.
A second major challenge is navigating the regulatory pathway for novel molecules with little or no IND precedent. This places a premium on thoughtful data generation and on linking structure, function, PK/PD and safety in a clear development rationale. Abzena is well positioned to support this through its breadth and depth of analytical, bioassay, developability, lead candidate selection and manufacturing capabilities.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO this year?
The key message I hope to share with industry stakeholders at BIO is that this is an exciting moment for drug development. Scientific innovation is opening up the possibility of treating diseases that have historically been very difficult to address, but success will depend on the ability to connect discovery, development, manufacturing and regulatory strategy from the outset.
In summary, the future of advanced therapeutics will be shaped by organizations that can combine scientific insight with practical execution. Abzena’s role is to help customers de-risk complex molecules, generate the right data, and build a scalable path from concept to clinic and ultimately to commercial supply.
Author: Sarah Stevens, CEO, Chrysalis
Q. What are the biggest trends currently shaping your organisation and the wider life sciences sector?
SS. I am seeing recent funding trends making it both a challenging and a fascinating time for life sciences. Reality is a growing disconnect between the pace of scientific innovation, the possibilities provided by curative therapies and the operating models used to support ‘downstream’ development and manufacturing.
Exciting advances continue across cell therapy, regenerative medicine and other ATMP modalities. The innovators and organizations driving such know-how and progress remain dependent on manufacturing infrastructure and service provider models that cannot keep pace, nor provide the necessary risk management, flexibility and control of processes. These factors are critical as beyond operational convenience or efficiency, they fundamentally define success, failure and the value of the innovative asset or organization. Moreover, classical manufacturing infrastructure and operating models are creating time and cost barriers between life enhancing, potentially curative therapies and patients.
Discussions around affordability and cost of goods are often framed as manufacturing challenges, but many of the underlying drivers stem from the in house or outsourced operating model itself – often oversized, underutilized facilities with labor-intensive operating structures.
The ability to develop and manufacture therapeutics should not be limited to organizations with the capital and scale to build and carry extensive infrastructure networks. At Chrysalis, we challenge these barriers entirely – our goal and operating platform ensure that infrastructure, processes and systems enable innovation rather than constrain it. Our platform serves such innovative companies both in our own facilities, or uniquely as a ‘lift and drop’ operating model in facilities other than our own.
Q. How are changing market conditions influencing your strategy and priorities for the coming year?
SS. Our priority at Chrysalis is to continue expanding access to our operating model, ensuring that we support companies to de-risk their investments in manufacturing. A large part of this is helping our customers to create GMP operating roadmaps that remain viable from early development through commercialization, reducing the disruption and inefficiency that can occur as programs transition between stages of growth.
Chrysalis’ inherent ability to adapt and flex with our customers means that we can remain steady and consistent despite the ups and downs of market influencing factors.
Q. What innovations or developments are you most excited about within your area of expertise?
SS. The scientific advances occurring across medicines development in general are incredible. We want to help unleash their potential and return for innovators, investors and most importantly, patients. I am passionate about the democratization of advanced therapies. Groundbreaking science should not be limited by practical challenges or unevolved thinking about manufacturing. Innovation is not only about discovering new therapies, it is also about building better systems to bring those therapies to life.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is your organisation helping to address them?
SS. One of the most frequently discussed challenges we discuss with innovators is cost of goods. We uniquely see the service provider side too, where it is difficult to flex necessary fixed cost across people, equipment, processes and systems. In both sides of this equation, it is often viewed as a manufacturing “capacity” problem, but more often than not it is actually an operating model problem.
In-house manufacturers and service providers routinely absorb significant costs associated with underutilized facilities, redundant quality systems, repeated technology transfers, fragmented supply chains, and infrastructure that was designed around projected future demand rather than actual program requirements. These costs ultimately find their way into the economics of the therapy.
At Chrysalis, we address this head-on with our GMP operating model – significantly rethinking how infrastructure and operational capabilities are deployed. With us, no one customer is covering excessive service provider costs, nor do we not contract in a manner that puts program longevity at risk. We provide customer owned access to fully operationalized GMP facilities, mature quality systems and experienced SME support. Alongside this and the customer manufacturing process, we provide all of the necessary GMP-enabling ancillary support and services, all of which can be scaled and adapted alongside the needs of the program.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO International this year?
SS. Today, breakthrough science is emerging from academic institutions, startups and small development-stage companies just as readily as it can from a large pharmaceutical organization. Our key message is that promising innovation, from any source, does not have to encounter barriers that have little to do with science itself. Our transformative approach to enabling progress provides the same significant benefits and value to all.
Author: Gregor Kawaletz, Chief Executive Officer of Mabion
Q. What are the biggest trends currently shaping your organization and the wider life sciences sector?
GK. Biopharma companies are under pressure to bring increasingly complex biologics to patients faster. More and more companies are turning to vendors to manage regulatory risk and production complexity. Customers are looking for partners who can contribute science, flexibility, and shared accountability. For CDMOs, this means manufacturing capacity alone is no longer enough.
At Mabion, this shift directly informs our strategy. We are focused on Drug Substance as our center of excellence. We build on our strongest experience in monoclonal antibodies and biosimilars, while expanding toward next-generation therapeutics such as ADCs through a carefully developed partner network. We also see rising demand for co-development models, where Mabion can share risks and future upside with customers. That is not a typical CDMO approach, and it is one of the ways we intend to differentiate ourselves in a crowded market. For biotech innovators Mabion can be more than a manufacturing vendor. We can be a development partner.
Q. How are changing market conditions influencing your strategy and priorities for the coming year?
GK. The market is moving toward more complex products where technical risk are high. Our strategy is designed around these realities. For the coming year, Mabion’s priorities are clear.
First, we are strengthening our position as a European Drug Substance Biologics Partner with strong quality and scalable manufacturing.
Second, we are expanding our value proposition beyond traditional fee-for-service work. For selected projects, we are open to co-development, meaning we can share risks, costs, and future profits with the client. This is particularly attractive for companies with promising assets but limited internal CMC resources or capital.
Third, we are using partnerships to broaden what we can offer without diluting our core focus. Our goal is to help customers move faster, reduce execution risk, and create long-term value together.
Q. What innovations or developments are you most excited about within your area of expertise?
GK. I am most excited by the convergence of biologics expertise, analytics, and partnership-driven development. Mabion’s heritage is in monoclonal antibodies and biosimilars, and that gives us a strong foundation for the next wave of complex biologics. Antibody-Drug Conjugates are a particularly exciting area because they combine the specificity of antibodies with highly targeted therapeutic payloads. They also demand exactly the kind of integrated thinking that Mabion brings: antibody development, process development, advanced analytics, quality systems, regulatory awareness, and partner coordination.
Another development I find highly promising is the evolution of co-development in the CDMO sector. Many biotech companies have excellent science but need a partner willing to engage earlier, think strategically, and share risk. Mabion is building this capability as a differentiator. We are not saying that every project should be co-developed, but for the right molecule, the right client, and the right market opportunity, it can align incentives much better than a standard service contract.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is your organisation helping to address them?
GK. The biggest challenge for many biopharma companies today is turning strong science into a manufacturable, fundable, and regulator-ready product. A molecule may be promising biologically, but without the right CMC strategy it can lose time, capital, and investor confidence. Companies must manage process development, analytics, comparability, quality, documentation, supply continuity, and regulatory expectations often with limited internal teams.
Mabion helps address this by acting as a flexible, science-driven CDMO partner. We can support projects from early development through process transfer, analytical development, GMP manufacturing, stability, comparability, and quality oversight. Our model allows customers to enter at different stages. Our ambition is simple: reduce complexity for clients and help bring high-quality biologics to patients faster.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO International this year?
GK. My key message at BIO International is that Mabion is ready to be a different kind of CDMO partner for biologics innovators. We bring almost two decades of biologics experience, strong roots in monoclonal antibodies and biosimilars and European GMP discipline. But what makes our story especially relevant now is our willingness to think beyond the traditional fee-for-service model.
For the right projects, Mabion can offer co-development: a model where we share risks and future profits with our partners. This is not the standard CDMO approach, and we believe it can be highly attractive for biotech companies that have promising assets but need a committed development and manufacturing partner to help unlock their value.
Author: Brad Rowe, Senior Director, Integrated Development, Quotient Sciences
Q. What are the biggest trends currently shaping your organisation and the wider life sciences sector?
BR. In a tighter funding environment, data must reduce risk and support investment. This is why biotech companies are prioritizing asset-specific development plans that generate early clinical data to guide later phase regulatory strategy and trial design. At the same time, CMC decisions around early formulation and manufacturability which consider scalability need to happen earlier to avoid delays later.
Q. What innovations or developments are you most excited about within your area of expertise?
BR. I’m excited to see how AI-designed drug development continues to progress in the months ahead. Quotient Sciences recently announced the start of a Phase I study on a drug product that we developed using artificial intelligence. It’s encouraging to see AI already helping optimize formulation design, support earlier decision-making, and potentially improve clinical outcomes as these capabilities continue to expand.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is your organisation helping to address them?
BR. Sponsors are prioritizing efficiency and de-risking development stages to remain competitive in an increasingly complex commercialization environment. This shift is towards more adaptive, asset-specific development strategies rather than rigid, linear plans.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO International this year?
BR. We expect that conversations will focus on designing development programs with integrated services, greater attention to evolving regulatory expectations, and controlling costs. Sponsors need to make early formulation and manufacturing decisions that will hold up through clinical progression. That puts greater emphasis on fit-for-purpose development, process understanding, and selecting partners who can align CMC activities with clinical and regulatory milestones from the outset.
Author: David Claveau, Vice President, Business Development, North America, Sygnature Discovery
Q. What are the biggest trends currently shaping your organisation and the wider life sciences sector?
DC. The sector is being defined by a shift toward early integration across discovery, development, chemistry, manufacturing and controls (CMC) and commercial strategy. Budgets are tight and timelines are reducing, meaning that investors must establish that a programme can differentiate and scale before committing to major spending. At Sygnature, these trends are leading to organisations shifting their behaviours to prioritise stronger target validation and earlier developability thinking, alongside more rigorous translational plans and clearer, data-driven go/no-go criteria.
Alongside this overall trend, automation and AI are maturing and evolving from abstract promises into practical tools that can actively shorten design-make-test-analyse (DMTA) cycles and enhance decision quality. This technological acceleration is supported by a widespread focus on operational resilience. Biopharma companies are moving away from fixed, siloed operating models and embracing flexible partner networks. This is driven by geopolitical uncertainty, supply-chain risks, increasing modality complexity and China’s emergence as an innovation engine. Biopharma companies can harness deep scientific expertise and operational adaptability to move rapidly without sacrificing quality and successfully navigate these industry trends.
Q. How are changing market conditions influencing your strategy and priorities for the coming year?
DC. There are welcoming signs of recovery in the biotech markets, including stronger M&A and public-market momentum. This optimism must be carefully balanced against ongoing regulatory uncertainty, pricing pressures and competition from China-originated assets. AI is often cited as a response to these solutions. Strategic priorities centre on maturing AI integration where it directly improves reproducibility, compresses timelines and enhances discovery decisions, moving past generic industry claims.
We are prioritising strategic partnership models in response to the changing market conditions. Very few emerging biotechs can afford to build every capability internally in the current funding environment, which establishes flexible outsourcing models as an operational necessity. Within these partnership models, early-stage translation remains a major theme, as generating the right translational data early enough prevents expensive, late-stage failures. Our strategy shifts the emphasis from simply doing more science to making sharper, faster decisions across the drug development path.
Q. What innovations or developments are you most excited about within your area of expertise?
DC. Developments that can enhance the speed and confidence of decision-making are the most exciting. These developments can be achieved by linking different capabilities together rather than treating them as separate workstreams. Innovation in decision-making can be driven by integrating target validation, translational biology, integrated medicinal chemistry, DMPK, structural and computational sciences, automation, AI-enabled design and robust project leadership.
We are also excited about modality-aware thinking. This involves developing distinct strategies tailored to the unique discovery and developability challenges of different modalities, including small molecules, biologics, peptides, targeted protein degradation (TPD) and antibody-drug conjugates (ADCs). Operational resilience is central to this approach. Providing programmes with flexible access to scalable capacity and specialised expertise enables teams to pivot quickly as new data emerges. The future of drug discovery and development belongs to teams that can seamlessly combine specialist depth with integrated execution, ensuring that computational insights are securely backed by solid laboratory evidence.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is your organisation helping to address them?
DC. Today’s biopharma companies face increasingly complex, capital-constrained environments. They must efficiently answer critical value-creating questions and build plans that convince investors, partners and potential future acquirers. Emerging biotechs often possess outstanding science and technical expertise but lack the infrastructure or specialist depth needed to manage the risks associated with this and evaluate developability early.
At Sygnature, we aim to address these challenges by transforming the traditional, transactional outsourcing model into integrated strategic partnerships. We can assist biopharma companies by operating as an extension of their team. This means contributing active scientific judgement and helping connect decisions across multiple disciplines. We also prioritise early value, designing disciplined experiments that answer critical project questions so that developability, translational strategy and differentiation shape the programme from day one.
A critical aspect of this approach is actively challenging the science rather than just executing tasks, which helps biopharma developers avoid false confidence and move forward faster and more safely. In this tight funding environment, we can provide the operational resilience and rigorous decision-making that biopharma developers need to advance credible candidates without building permanent, costly internal infrastructure.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO International this year?
DC. At BIO International, our key message centres on driving tangible impact through advanced AI integration. We are proud to reveal our strategic collaboration with DaltonTx, an AI technology company, designed to strengthen our AI-enabled drug discovery and accelerate medicinal chemistry decision-making while fully safeguarding customer data. This collaboration brings connected learning systems to the forefront, complementing our existing AI toolkit. The Dalton platform unifies data, models and experimental results to capture what worked and what failed.
As part of this collaboration, we are performing a retrospective evaluation of a legacy oncology programme, now a Phase I clinical candidate, to demonstrate how the platform reduces synthesis burden and shortens DMTA cycles. Unlike standalone applications, Dalton uses a secure natural language interface powered by agentic AI, allowing scientists to drive problem-solving through conversational workflows.
The industry is understandably concerned with data security. All customer data and AI models are strictly compartmentalised on a per-programme basis to ensure proprietary data is never used to train models for other projects. We believe the future of AI in drug discovery lies in combining machine learning with human scientific intuition to deliver measurable, secure value for our partners and their patients.
Q. What are the biggest trends currently shaping your organisation and the wider life sciences sector?
HZ. The biggest trend is the growing gap between scientific ambition and development reality.
Biotechs are advancing more targeted, more complex, and more technically demanding medicines than ever before. These are not straightforward programs. Many arrive with solubility limitations, difficult solid-state behaviour, complex absorption profiles, high potency, sterile requirements, or analytical challenges that are not yet fully understood.
At the same time, the pressure around these programs is increasing. Timelines are tight. Funding is selective. Regulatory expectations are evolving. Clients need to generate meaningful data quickly, but they cannot afford the cost of weak decisions made early.
This is the development reality Ardena is built to address.
We work on programs where complexity is not an exception, but the starting point. Our work brings together solid-state chemistry, formulation development, nanomedicines, drug substance and drug product manufacturing, bioanalysis, and CMC regulatory support. The value is not simply having these services available. The value is the continuity of scientific thinking across them.
The wider sector is moving beyond the idea that development is a linear handover between functions. For complex medicines, that model creates gaps. The programs that progress best are the ones where formulation strategy, analytical insight, manufacturability, bioanalytical data, and regulatory thinking are connected early.
That is the environment Ardena is focused on. We know development because we work in the difficult parts of it every day.
Q. How are changing market conditions influencing your strategy and priorities for the coming year?
HZ. Changing market conditions are making development discipline more important.
Biotech companies are under pressure to show clear progress, but that pressure is not only financial. It is scientific, clinical, regulatory, and operational. Programs need to move efficiently, but they also need to generate the right data, at the right time, to support the next decision
That is influencing how clients work with Ardena, and how we prioritise our support.
The conversation is no longer simply about moving fast. It is about moving with technical purpose. Speed only creates value when the underlying strategy is sound. Moving quickly with the wrong formulation approach, an incomplete analytical package, or an unresolved manufacturability issue can create larger delays later.
Our priority is to help clients make the right choices at the right time. Not every program needs everything at once. Some need rapid enabling work to reach the clinic. Others need deeper investigation into solubility, solid form, stability, delivery technology, process robustness, or regulatory positioning before the next step is taken.
This is where experienced development judgement matters. Ardena helps clients understand what must be solved now, what can be staged, and where risk is likely to appear later.
Efficiency in this market is not about cutting corners. It is about protecting capital, protecting timelines, and making sure the work being done actually supports the next milestone.
Q. What innovations or developments are you most excited about within your area of expertise?
HZ. The most exciting developments are happening where formulation science, advanced delivery technologies, and bioanalytical insight come together.
Many of the molecules entering development today have strong therapeutic potential, but difficult developability profiles. They may present challenges around solubility, absorption, stability, targeting, manufacturability, or measurement in the right biological context. These are development problems, and they are problems we can increasingly solve with better tools, better data, and better integration.
Nanomedicine is a strong example. Lipid-based systems, nanoparticle technologies, and complex injectable platforms are becoming increasingly important for molecules that would otherwise struggle with solubility, absorption, stability, or targeting. For many modern therapies, these technologies are central to whether the program can reach therapeutic levels in the clinic.
What makes this powerful is the connection to the rest of development. Solid-state chemistry and preformulation help us understand the molecule. Formulation science gives us the strategy. Manufacturing expertise tells us whether that strategy can be scaled and controlled. Bioanalysis tells us what the drug is actually doing in vivo.
We are also interested in the practical use of AI and data analytics. Not as slogans, and not as replacements for scientific judgement. Their value is in helping teams see patterns earlier, compare outcomes more effectively, and capture knowledge across workstreams.
The real innovation is not one technology in isolation. It is the ability to turn complex science into better development decisions, faster.
Q. What do you see as the biggest challenges facing biopharma companies today, and how is your organisation helping to address them?
HZ. The biggest challenge is uncertainty.
A biopharma company may have a molecule with strong therapeutic potential, but early development is full of unknowns. Will the molecule dissolve? Which solid form is viable? Can it be formulated for the intended route? Can it be manufactured reproducibly? Can it be measured accurately in biological matrices? Will the development package support the next regulatory, clinical, or partnering decision?
These questions arrive at exactly the moment when programs need momentum.
That is where mistakes become expensive. A weak assumption made in early phase can become a clinical supply issue, a failed formulation strategy, a regulatory question, or a delay that could have been avoided. The problem is not only technical execution. It is knowing which risks matter before they become visible.
Ardena helps by bringing integrated scientific judgement to that window.
We connect solid-state chemistry, formulation development, advanced drug delivery, drug substance and drug product manufacturing, bioanalysis, and CMC regulatory support. That means decisions are not made in isolation. Data from one workstream informs the next. Assumptions are challenged early. Gaps are identified while there is still time to correct them.
For biopharma companies, that creates practical value. It helps them advance with a development plan that is technically sound, stage-appropriate, and built around the next milestone.
Our role is not just to do the work. It is to help clients see around corners.
Q. What key message or insight are you hoping to share with industry stakeholders at BIO International this year?
HZ. The message we want to share at BIO International is simple: complex molecules need more than capacity.
They need development judgement.
The programs coming through the biopharma pipeline are harder to formulate, harder to characterise, harder to manufacture, and harder to move through regulatory review. Many are targeting oncology, rare diseases, and precision medicine opportunities where timelines are tight and patient need is high. The science is strong, but the development path is rarely straightforward.
That is exactly where Ardena is built to operate.
We solve the development challenges that sit between promising science and clinical reality: complex solid-state chemistry, poor solubility, advanced formulation, nanomedicines, HPAPIs, sterile dosage forms, bioanalytical measurement, and CMC regulatory strategy. These are not separate service lines in practice. They are connected decisions that determine whether a program progresses with confidence.
The insight we want to bring to industry stakeholders is that early development is where value is protected or lost. The right formulation strategy, analytical approach, manufacturing plan, and regulatory thinking can protect time, budget, and long-term product potential.
Your molecule may be complex. Your timeline may be tight. That is our problem to help solve.
We will be at booth 3253 and welcome conversations with companies working through these development challenges.
